Join Growin Stock Community!

Nephros, inc.NEPH.US Overview

US StockHealthcare
(No presentation for NEPH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NEPH AI Insights

NEPH Overall Performance

NEPH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NEPH Recent Performance

-0.29%

Nephros, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NEPH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NEPH Key Information

NEPH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NEPH Profile

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Price of NEPH

NEPH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NEPH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.14
PE Ratio (TTM)
27.93
Forward PE
-
PS Ratio (TTM)
2.32
PB Ratio
4.28
Price-to-FCF
15.95
METRIC
VALUE
vs. INDUSTRY
Gross Margin
63.24%
Net Margin
8.26%
Revenue Growth (YoY)
32.36%
Profit Growth (YoY)
37.13%
3-Year Revenue Growth
25.52%
3-Year Profit Growth
56.40%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.14
PE Ratio (TTM)
27.93
Forward PE
-
PS Ratio (TTM)
2.32
PB Ratio
4.28
Price-to-FCF
15.95
Gross Margin
63.24%
Net Margin
8.26%
Revenue Growth (YoY)
32.36%
Profit Growth (YoY)
37.13%
3-Year Revenue Growth
25.52%
3-Year Profit Growth
56.40%
  • When is NEPH's latest earnings report released?

    The most recent financial report for Nephros, inc. (NEPH) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NEPH's short-term business performance and financial health. For the latest updates on NEPH's earnings releases, visit this page regularly.

  • Where does NEPH fall in the P/E River chart?

    According to historical valuation range analysis, Nephros, inc. (NEPH)'s current price-to-earnings (P/E) ratio is 37.31, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of NEPH?

    According to the latest financial report, Nephros, inc. (NEPH) reported an Operating Profit of 314K with an Operating Margin of 6.59% this period, representing a growth of 52.43% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NEPH's revenue growth?

    In the latest financial report, Nephros, inc. (NEPH) announced revenue of 4.76M, with a Year-Over-Year growth rate of 35.42%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NEPH have?

    As of the end of the reporting period, Nephros, inc. (NEPH) had total debt of 1.15M, with a debt ratio of 0.09. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NEPH have?

    At the end of the period, Nephros, inc. (NEPH) held Total Cash and Cash Equivalents of 5.17M, accounting for 0.39 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NEPH go with three margins increasing?

    In the latest report, Nephros, inc. (NEPH) achieved the “three margins increasing” benchmark, with a gross margin of 61.2%%, operating margin of 6.59%%, and net margin of 7.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NEPH's profit trajectory and future growth potential.

  • Is NEPH's EPS continuing to grow?

    According to the past four quarterly reports, Nephros, inc. (NEPH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NEPH?

    Nephros, inc. (NEPH)'s Free Cash Flow (FCF) for the period is 99K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 115.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NEPH?

    The latest valuation data shows Nephros, inc. (NEPH) has a Price-To-Earnings (PE) ratio of 37.31 and a Price/Earnings-To-Growth (PEG) ratio of 1.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.